Skip to main content
Erschienen in: Cancer Causes & Control 5/2019

16.03.2019 | Original Paper

Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2− breast cancer subtypes

verfasst von: Carol A. Parise, Vincent Caggiano

Erschienen in: Cancer Causes & Control | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study compared the demographic and clinicopathologic characteristics and risk of mortality between the triple positive (TP) and ER+/PR+/HER2− breast cancer subtypes.

Methods

Cases of first primary female invasive TP and ER+/PR+/HER2− breast cancer were obtained from the California Cancer Registry. Logistic regression analysis was used to compare differences in factors associated with the TP versus the ER+/PR+/HER2− subtype. Cox regression was used to compute the adjusted risk of breast cancer-specific mortality of the TP versus ER+/PR+/HER2−.

Results

The odds of TP versus ER+/PR+/HER2− were higher with advanced stage, high grade, low SES, ≤ 45 years of age (OR 1.48; CI 1.40–1.55), black (OR 1.11; CI 1.02–1.21), Asian/Pacific Islander (OR 1.15; CI 1.09–1.22), and uninsured (OR 1.42; CI 1.15–1.73). Unadjusted survival analysis indicated worse survival for the TP when compared with the ER+/PR+/HER2− subtype. However, adjusted risk of mortality for the TP subtype was not statistically significantly worse than the ER+/PR+/HER2− subtype.

Conclusions

Young age, advanced stage and grade, low SES, black and API race, and lack of health insurance are more common in the TP subtype than in the ER+/PR+/HER2− subtype. However the risk of mortality between these two subtypes is similar.
Literatur
1.
Zurück zum Zitat Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J 15:593–602CrossRefPubMed Parise CA, Bauer KR, Brown MM, Caggiano V (2009) Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999–2004. Breast J 15:593–602CrossRefPubMed
2.
Zurück zum Zitat Parise CA, Caggiano V (2014) Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J. Cancer Epidemiol 2014:469251CrossRefPubMedPubMedCentral Parise CA, Caggiano V (2014) Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J. Cancer Epidemiol 2014:469251CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728CrossRefPubMed Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728CrossRefPubMed
4.
Zurück zum Zitat Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(Suppl 6):vi7–12CrossRefPubMed Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(Suppl 6):vi7–12CrossRefPubMed
5.
Zurück zum Zitat Liao HY, Zhang WW, Sun JY, Li FY, He ZY, Wu SG (2018) The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer 9:296–303CrossRefPubMedPubMedCentral Liao HY, Zhang WW, Sun JY, Li FY, He ZY, Wu SG (2018) The clinicopathological features and survival outcomes of different histological subtypes in triple-negative breast cancer. J Cancer 9:296–303CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502CrossRefPubMed Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502CrossRefPubMed
7.
Zurück zum Zitat Parise CA, Caggiano V (2017) Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities. Breast Cancer Res Treat 163:151–158CrossRefPubMed Parise CA, Caggiano V (2017) Risk factors associated with the triple-negative breast cancer subtype within four race/ethnicities. Breast Cancer Res Treat 163:151–158CrossRefPubMed
8.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedPubMedCentral Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedPubMedCentral
9.
Zurück zum Zitat Urru SAM, Gallus S, Bosetti C et al (2018) Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer 18:56CrossRefPubMedPubMedCentral Urru SAM, Gallus S, Bosetti C et al (2018) Clinical and pathological factors influencing survival in a large cohort of triple-negative breast cancer patients. BMC Cancer 18:56CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Zhao S, Ma D, Xiao Y, Jiang YZ, Shao ZM (2018) Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis. Eur J Surg Oncol 44(4):420–428CrossRefPubMed Zhao S, Ma D, Xiao Y, Jiang YZ, Shao ZM (2018) Clinicopathologic features and prognoses of different histologic types of triple-negative breast cancer: a large population-based analysis. Eur J Surg Oncol 44(4):420–428CrossRefPubMed
11.
Zurück zum Zitat Fritz AG (2000) International classification of diseases for oncology: ICD-O, 3rd edn. World Health Organization, Geneva, pp. vi, 239 Fritz AG (2000) International classification of diseases for oncology: ICD-O, 3rd edn. World Health Organization, Geneva, pp. vi, 239
12.
Zurück zum Zitat California Department of Public, Cancer Surveillance and Research Branch (2008) Cancer reporting in California: abstracting and coding procedures for hospitals. California cancer reporting system standards, vol. I. California Department of Public, Cancer Surveillance and Research Branch, Sacramento California Department of Public, Cancer Surveillance and Research Branch (2008) Cancer reporting in California: abstracting and coding procedures for hospitals. California cancer reporting system standards, vol. I. California Department of Public, Cancer Surveillance and Research Branch, Sacramento
17.
Zurück zum Zitat Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711CrossRefPubMed Yost K, Perkins C, Cohen R, Morris C, Wright W (2001) Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 12:703–711CrossRefPubMed
18.
Zurück zum Zitat Clarke CA, Glaser SL, Keegan TH, Stroup A (2005) Neighborhood socioeconomic status and Hodgkin’s lymphoma incidence in California. Cancer Epidemiol Biomark Prev 14:1441–1447CrossRef Clarke CA, Glaser SL, Keegan TH, Stroup A (2005) Neighborhood socioeconomic status and Hodgkin’s lymphoma incidence in California. Cancer Epidemiol Biomark Prev 14:1441–1447CrossRef
19.
Zurück zum Zitat Parikh-Patel A, Bates JH, Campleman S (2006) Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988–2000. Cancer 107:1189–1195CrossRefPubMed Parikh-Patel A, Bates JH, Campleman S (2006) Colorectal cancer stage at diagnosis by socioeconomic and urban/rural status in California, 1988–2000. Cancer 107:1189–1195CrossRefPubMed
20.
Zurück zum Zitat Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H (2007) Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomark Prev 16:546–552CrossRef Zell JA, Rhee JM, Ziogas A, Lipkin SM, Anton-Culver H (2007) Race, socioeconomic status, treatment, and survival time among pancreatic cancer cases in California. Cancer Epidemiol Biomark Prev 16:546–552CrossRef
21.
Zurück zum Zitat Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004. Cancer 112:737–747CrossRefPubMed Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999–2004. Cancer 112:737–747CrossRefPubMed
22.
Zurück zum Zitat Ou SH, Zell JA, Ziogas A, Anton-Culver H (2008) Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer 112:2011–2020CrossRefPubMed Ou SH, Zell JA, Ziogas A, Anton-Culver H (2008) Low socioeconomic status is a poor prognostic factor for survival in stage I nonsmall cell lung cancer and is independent of surgical treatment, race, and marital status. Cancer 112:2011–2020CrossRefPubMed
23.
Zurück zum Zitat Yin D, Morris C, Allen M, Cress R, Bates J, Liu L (2010) Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups? Cancer Causes Control 21:1721–1730CrossRefPubMedPubMedCentral Yin D, Morris C, Allen M, Cress R, Bates J, Liu L (2010) Does socioeconomic disparity in cancer incidence vary across racial/ethnic groups? Cancer Causes Control 21:1721–1730CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Telli ML, Chang ET, Kurian AW et al (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 127:471–478CrossRefPubMed Telli ML, Chang ET, Kurian AW et al (2011) Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat 127:471–478CrossRefPubMed
25.
Zurück zum Zitat Parise CA, Bauer KR, Caggiano V (2012) Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. Cancer 118:2516–2524CrossRefPubMed Parise CA, Bauer KR, Caggiano V (2012) Disparities in receipt of adjuvant radiation therapy after breast-conserving surgery among the cancer-reporting regions of California. Cancer 118:2516–2524CrossRefPubMed
26.
Zurück zum Zitat Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefPubMed
27.
Zurück zum Zitat Hosmer D, Lemeshow S (1989) Applied logistic regression. Wiley, New York Hosmer D, Lemeshow S (1989) Applied logistic regression. Wiley, New York
28.
Zurück zum Zitat IBM Corp (2012) IBM SPSS statistics for Windows, vol 21.0. IBM Corp., Armonk IBM Corp (2012) IBM SPSS statistics for Windows, vol 21.0. IBM Corp., Armonk
29.
Zurück zum Zitat Alqaisi A, Chen L, Romond E et al (2014) Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Res Treat 148:437–444CrossRefPubMed Alqaisi A, Chen L, Romond E et al (2014) Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. Breast Cancer Res Treat 148:437–444CrossRefPubMed
30.
Zurück zum Zitat Alwan NAS, Mualla FH, Al Naqash M, Kathum S, Tawfiq FN, Nadhir S (2017) Clinical and pathological characteristics of triple positive breast cancer among Iraqi patients. Gulf J Oncol 1:51–60 Alwan NAS, Mualla FH, Al Naqash M, Kathum S, Tawfiq FN, Nadhir S (2017) Clinical and pathological characteristics of triple positive breast cancer among Iraqi patients. Gulf J Oncol 1:51–60
31.
Zurück zum Zitat Parise CA, Caggiano V (2017) Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer Res Treat 165:743–750CrossRefPubMed Parise CA, Caggiano V (2017) Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors. Breast Cancer Res Treat 165:743–750CrossRefPubMed
32.
Zurück zum Zitat Tamimi RM, Baer HJ, Marotti J et al (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67CrossRefPubMedPubMedCentral Tamimi RM, Baer HJ, Marotti J et al (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Ades F, Zardavas D, Bozovic-Spasojevic I et al (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32:2794–2803CrossRefPubMed Ades F, Zardavas D, Bozovic-Spasojevic I et al (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32:2794–2803CrossRefPubMed
34.
36.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedPubMedCentral Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874CrossRefPubMedPubMedCentral Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423CrossRefPubMedPubMedCentral Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat Sotiriou C, Neo SY, McShane LM et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398CrossRefPubMedPubMedCentral Sotiriou C, Neo SY, McShane LM et al (2003) Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100:10393–10398CrossRefPubMedPubMedCentral
Metadaten
Titel
Differences in clinicopatholgic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2− breast cancer subtypes
verfasst von
Carol A. Parise
Vincent Caggiano
Publikationsdatum
16.03.2019
Verlag
Springer International Publishing
Erschienen in
Cancer Causes & Control / Ausgabe 5/2019
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-019-01152-8

Weitere Artikel der Ausgabe 5/2019

Cancer Causes & Control 5/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.